The Next Alzheimer’s Breakthrough Will Take More Than Just Science
Alzheimer's research has made significant strides with drugs like Lecanemab and Donanemab showing potential to slow cognitive decline by targeting amyloid plaques, but challenges remain in early diagnosis and equitable access to treatment. Pioneering researcher John Hardy emphasizes that scientific advances alone are insufficient—improved diagnostics, political will, and investment in dementia services are crucial for progress. While anti-amyloid therapies mark a turning point, they extend rather than halt disease progression, underscoring the need for more effective treatments and broader systemic support.
Opening excerpt (first ~120 words) tap to expand
Anna McKieScienceMay 1, 2026 2:55 PMThe Next Alzheimer’s Breakthrough Will Take More Than Just ScienceAt WIRED Health, pioneering Alzheimer's researcher John Hardy outlined the stakes—and next steps—of where treatment is headed next.Photograph: FERNANDO BRAZCommentLoaderSave StorySave this storyCommentLoaderSave StorySave this storyAlzheimer’s research is entering a new phase, as treatments that have taken decades to develop begin to reach patients. But getting those advances to people will depend on more than scientific progress alone, according to pioneering Alzheimer’s researcher John Hardy.Speaking at WIRED Health in April, Hardy, chair of the Molecular Biology of Neurological Disease at University College London, said that alongside more effective drugs, better diagnosis and…
Excerpt limited to ~120 words for fair-use compliance. The full article is at WIRED.
Discussion
0 commentsMore from WIRED
